Kiniksa Pharmaceuticals International, plc KNSA
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) is an immunology/inflammation drug developer. Its lead program, ARCALYST (rilonacept), is in Phase 3 for Recurrent pericarditis. Its next catalyst on record is KPL-1161: Enter Phase 1 (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: KPL-1161 — Enter Phase 1 (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ARCALYST (rilonacept) | Recurrent pericarditis; CAPS; DIRA | protein/peptide | Approved |
| KPL-387 | Recurrent pericarditis (PASTORALE Phase 3) | antibody | Phase 3 |
| KPL-1161 | Undisclosed | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
- AbbVie Inc. ABBV
- Sanofi SNY
- Argenx SE ARGX
- Roivant Sciences Ltd. ROIV
- Immunovant, Inc. IMVT
- Dianthus Therapeutics, Inc. DNTH
- Celldex Therapeutics, Inc. CLDX
- Biocryst Pharmaceuticals Inc BCRX
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.